Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia and insulin resistance. There are several rodent models of type 2 diabetes, and db/db mice are extensively used to demonstrate the efficacy of anti-diabetic compounds. db/db mice are leptin receptor deficient, and due to the lack of leptin signaling in the hypothalamus, these mice become hyperphagic and develop obesity with consequently high leptin and insulin levels. At 4 weeks of age, db/db mice show increased fat deposition in the inguinal and axillary regions. Hyperinsulinemia is evident at 2 weeks, and hyperglycemia by 4-8 weeks of age. At 5-6 months of age, body weight and insulin levels begin to reduce in association with pancreatic islet cell degeneration.
We offer preclinical efficacy, proof-of-concept, and mechanism of action studies with your drug candidates. We work with our clients in providing scientific guidance, customized study design, end-point analysis, histopathology services, and will assist you with professional interpretation of the data. Please contact us with your specific needs.
Relevant publications by our scientists:
1. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Hepatology. 2007 Jun;45(6):1366-74. PMID: 17476695
2. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Hepatology. 2008 Feb;47(2):625-35. PMID: 18000880